Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.
Department of Translational Hematology and Oncology Research.
Ali
A
Tabarroki
Yogen
Y
Saunthararajah
Valeria
V
Visconte
Tracy
T
Cinalli
Kristin
K
Colaluca
Heesun J
HJ
Rogers
Mikkael A
MA
Sekeres
Hien K
HK
Duong
Brady L
BL
Stein
Ramon V
RV
Tiu
D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D000077209:Decitabine; D005221:Fatigue / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000473:pathology; D011720:Pyrazoles / Q000008:administration & dosage; D011743:Pyrimidines; D012074:Remission Induction; D016896:Treatment Outcome
D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; D000077209:Decitabine; C540383:ruxolitinib; D015254:DNA Modification Methylases; D001374:Azacitidine